Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why

Shares of Zentalis Pharmaceuticals, Inc. (ZNTL) have plunged 71.7% in the past three months against the industry's growth of 6.2%. The company is developing its lead product candidate, azenosertib, a potentially first-in-class WEE1 inhibitor, as a monotherapy and in combination with other therapies for treating different types of cancer indications, including solid tumors and ovarian cancer. In June 2024, the FDA placed a partial clinical hold on three studies evaluating azenosertib for three different canc ...